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Available online 12 July 2017Toxoplasma gondii infection is associatedwith increased risk for psychosis. However, the possible association be-
tween T. gondii and psychotic-like symptoms in the general adult population is unknown.
We investigated whether T. gondii is associated with psychotic-like symptoms and psychosis diagnoses using
data from Health 2000, a large cross-sectional health survey of the Finnish general population aged 30 and
above. Seropositivity to toxoplasma was defined as a cutoff of 50 IU/ml of IgG antibodies. Lifetime psychotic-
like symptoms were identified with section G of the Composite International Diagnostic Interview, Munich ver-
sion (M-CIDI). Symptoms were considered clinically relevant if they caused distress or help-seeking or there
were at least three of them. Lifetime psychotic disorders were screened from the sample and were diagnosed
with DSM-IV using SCID-I interview and information frommedical records. All data were available for 5906 par-
ticipants.We adjusted for variables related to T. gondii seropositivity (age, gender, education, region of residence,
cat ownership, and C-reactive protein measuring inflammation) in regression models.
We found that T. gondii seropositivity was significantly associated with clinically relevant psychotic-like symp-
toms (OR 1.77, p= 0.001) and with the number of psychotic-like symptoms (IRR= 1.55, p= 0.001). The asso-
ciation between toxoplasma and diagnosed psychotic disorders did not reach statistical significance (OR 1.45 for
schizophrenia).
In a large sample representing the whole Finnish adult population, we found that serological evidence of toxo-
plasma infection predicted psychotic-like symptoms, independent of demographic factors and levels of C-reac-
tive protein. Toxoplasma infection may be a risk factor for manifestation of psychotic-like symptoms.






Toxoplasma gondii (T. gondii) infection is associated with increased
risk of psychosis (Yolken and Torrey, 2008). In a recent meta-analysis,
T. gondii seropositivity was associated with schizophrenia (odds ratio
(OR) 1.8, 95% confidence interval (CI) 1.5–2.2) and with bipolar disor-
der (OR 1.5, 95% CI 1.1–2.2) (Sutterland et al., 2015). The ORwas higher
in patients with recent-onset than in chronic schizophrenia. High
serointensity was associated with higher odds of schizophrenia, and
the OR also varied by region, decreasing with higher seroprevalence in
the population (Sutterland et al., 2015).th and Welfare, Mental HealthIncreased risk of toxoplasma infection before the onset of schizo-
phrenia was reported in the meta-analysis by Sutterland et al. (2015)
with 1.3 OR (95% CI 1.1–1.6). However, fewer studies have investigated
whether T. gondii is associated with subclinical psychotic-like symp-
toms, which may indicate subsequent psychosis risk (Schultze-Lutter
et al., 2015). High serointensity associated with higher OR for schizo-
phrenia, and the OR also varied by region and by the seroprevalence
in the general population. In a Dutch adolescent population-based
cohort study, toxoplasma was not associated with subclinical psychotic
symptoms (Wang et al., 2011). In contrast, in young people at ultra-high
risk (UHR) for psychosis, seropositivity to T. gondii related to more
severe psychiatric symptoms and positive symptoms (Amminger et
al., 2007).
In this study, we used data from a large Finnish general population
survey to investigate whether T. gondii seropositivity and serointensity
are associated with psychotic disorders and with subclinical
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Data used in this study was from the Health 2000 (BRIF8901), a na-
tionally representative survey of the Finnish population conducted in
2000–2001 (Aromaa and Koskinen, 2004). Adults aged 30 years and
over were sampled using stratified two-staged cluster sampling (N =
8028). Individuals were chosen to the study to be representative of
their age and gender group in the area where they lived. The protocol
included a home interview and health examination at the local health
care center or, for those unable to attend, a condensed interview and
health examination at home or in an institution (Aromaa and
Koskinen, 2004). Fig. 1 shows the participantflowdiagram in theHealth
2000 survey.
All participants gave written informed consent and the study was
approved by the ethics committees of the Hospital District of Helsinki
and Uusimaa and the National Institute for Health and Welfare.
2.2. Toxoplasma
Plasma samples were collected as a part of the participants' health
examination. Immunoglobulin G (IgG) antibodies against T. gondii, indi-
cating previous infection, were performed by solid phase enzyme im-
munoassay. Whole tachyzoite lysate from Ross South Labs, Spanish
Fork Utah, USA was used, employing methods as previously described
by Dickerson et al. (2007). Comparisons to standards with known levels
of antibody were used to convert sample values to international units.
We used 50 IU/ml as the cut-off for seropositivity, as in Sugden et al.Fig. 1. Participant flow diagram(2016). In addition, serointensity, defined as the quantitative level of
antibody in IU/ml, was analyzed as a continuous variable.
2.3. Psychotic-like symptoms
Lifetime psychotic-like symptoms were assessed using the
Finnish translation of the Composite International Diagnostic
Interview, Munich version (M-CIDI) (Wittchen et al., 1998), which
was a part of the health examination (Pirkola et al., 2005).
Psychotic-like symptoms were assessed in section G of the interview.
Participants were shown with a list of 23 psychotic-like experiences
(Table 1) and asked if they had ever experienced any of them. Five of
the experiences are hallucinatory (17–21) and 16 delusional (1–14),
with two symptoms (22 and 22A) probing catatonic-like symptoms.
If any of the presented symptoms were endorsed, questions
concerning the clinical relevance of the experiences were asked.
Using a previously formed definition (Perälä et al., 2007), symptoms
were considered clinically relevant if the person reported at least
three symptoms, if the person had discussed the symptom(s) with
a doctor or other professional, or if the symptom(s) had interfered
with normal life.
In addition, the number of psychotic-like experiences reported by the
person (0–23 symptoms)was used as a continuous variable in this study.
2.4. Psychotic disorders
Lifetime psychotic disorders were identified from the Psychoses in
Finland study, which was a substudy of the Health 2000 survey (Perälä
et al., 2007). Psychotic disorders were screened from the Health 2000
sample using the M-CIDI (clinically relevant symptoms as defined earli-
er), self-reported diagnoses, medical examination, and national register.
The register screen included hospital treatment because of a diagnosis
of any psychotic or bipolar disorder, free outpatient antipsychoticmedica-
tion for severe psychotic and other severemental disorders, and disabilityin the Health 2000 study.
Table 1
The questions assessing psychotic-like symptoms with endorsement proportions.
Symptom % [95% CI]
1. Have you ever believed people were spying on you? 0.81 [0.57, 1.05]
2. Was there ever a time when you believed people were following you? 2.21 [1.85, 2.57]
2B. Have you been convinced that people you saw talking to each other were talking about you or laughing at you? 6.52 [5.81, 7.23]
3. Have you ever believed that you were being secretly tested or experimented on? 0.30 [0.15, 0.44]
4. Have you ever believed that someone was plotting against you or trying to hurt you or poison you? 1.51 [1.21, 1.81]
5. Have you ever been convinced that someone you had not met was in love with you? 0.55 [0.35, 0.76]
6. Have you ever been unreasonably convinced that your spouse or partner was being unfaithful, although ^AS1^ told you that was not true? 2.48 [2.05, 2.91]
7. Have you ever believed that someone was reading your mind? 1.50 [1.15, 1.85]
8. Have you ever been convinced you could actually hear what another person was thinking, even though he or she was not speaking? 0.37 [0.20, 0.53]
9. Have you ever been convinced that others could hear your thoughts? 0.28 [0.16, 0.40]
10. Have you ever been convinced that you were under the control of some power or force, so that your actions and thoughts were not your own? 0.84 [0.62, 1.05]
11. Have you ever been convinced that strange thoughts, or thoughts that were not your own, were being put directly into your mind? 0.24 [0.12, 0.37]
12. Have you ever been convinced that someone or something could take or steal your thoughts out of your mind? 0.14 [0.04, 0.23]
13. Have you ever been convinced that you were being sent special messages through television or the radio, or that a program had been arranged
just for you alone?
0.24 [0.11, 0.37]
13B. Have you felt that a book, or newspaper, or song was meant only for you and no one else? 0.42 [0.25, 0.59]
14. Have you ever felt strange forces working on you, as if you were being hypnotised or magic was being performed on you, or you were being hit
by X-rays or laser beams?
0.66 [0.43, 0.88]
17. Have you ever seen something or someone that others who were present could not see — that is, had a vision or hallucination when you were
completely awake?
0.88 [0.64, 1.12]
18. Have you more than once heard things other people couldn't hear, for example sounds or something like a voice? 0.83 [0.61, 1.05]
20. Have you ever been bothered by strange smells around you that nobody else seemed to be able to smell, perhaps even unusual odours
coming from your own body?
0.42 [0.26, 0.59]
20C. Have you ever had strange tastes in your mouth that could not be explained by anything you had eaten or put in your mouth? 0.25 [0.12, 0.37]
21. Have you ever had unusual feelings on your skin or inside your body — like being touched when nothing was there or feeling
something moving inside your body?
0.96 [0.72, 1.20]
22. Have you ever had a time when you were unable to move at all when it wasn't due to a physical or other medical reason? 0.27 [0.14, 0.40]
22A. Have you ever had a time when you moved constantly and couldn't stop when it wasn't due to a physical or other medical reason? 0.44 [0.27, 0.61]
CI, confidence intervals.
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pressive disorder. Those selected by the screenswere then re-interviewed
with the Structured Clinical Interview for DSM-IV (SCID-I, First et al.,
1997). Best-estimate DSM-IV diagnoseswere formed by combining infor-
mation from the SCID interview with information from all medical re-
cords from lifetime mental health treatment contacts. A graphical
presentation on the participants in the Psychoses in Finland study can
be seen in the Supplementary Fig. 1.
Participants were grouped as follows (number of those with
available plasma samples in parenthesis): 1) any psychotic disorder
(N=155), 2) functional psychosis (not substance induced or caused
by a general medical condition,N=132), 3) schizophrenia (N=41),
4) non-affective psychosis other than schizophrenia (schizoaffective
disorder, schizophreniform disorder, psychotic disorder not
otherwise specified, brief psychotic disorder, or delusional disorder,
N = 56), or 5) affective psychosis (bipolar I disorder or major
depressive disorder with psychotic features, N = 35).
2.5. Other variables
We used age, sex, education, and region of residence as
sociodemographic variables in the analyses. Education was classified
as basic (only compulsory) education, secondary education (high
school, vocational education), and high education (degree from higher
vocational institutions, polytechnics or universities) (Aromaa and
Koskinen, 2004). Current region of residence was categorized based
on the university hospital districts as Northern, Eastern, Western,
Southwestern, and Southern Finland.
Cat ownership was asked about in a questionnaire and categorized
as current, previous, and never. This variablewas used in themodels be-
cause domestic cats are a potential source of toxoplasma infection and
cats in Finland commonly are seropositive for toxoplasma (Jokelainen
et al., 2012). In our previous work, we found an association between
cat ownership and T. gondii (Suvisaari et al., 2017). Previous studies
have found an association of childhood cat ownership with laterschizophrenia (Torrey et al., 2015), but not to psychotic symptoms in
adolescence (Solmi et al., 2017).
Serum high-sensitivity C-reactive protein (CRP) level was used to
measure inflammation as described previously (Heikkilä et al., 2011).
It was analyzed from serum samples taken at the same time as plasma
samples from which toxoplasma antibodies were measured. Higher
CRP levels were associated with T. gondii seropositivity in our previous
study (Suvisaari et al., 2017).2.6. Statistical analysis
Statistical analyses were conducted taking into account the two-
stage cluster sampling design using Intercooled Stata 11.0 (StataCorp,
2009). In addition, poststratification weights were used to adjust for
the oversampling of individuals aged 80 years and over and non-
response.
The presence of clinically relevant psychotic-like symptoms, the
number of psychotic-like symptoms and the prevalences of psychosis
diagnoses in the toxoplasma seropositive and seronegative groups
were calculated as predictive margins from logistic regression analysis
or negative binomial model adjusting for age and sex (Graubard and
Korn, 1999). Linear regression was used to calculate group differences
in age and serointensity.
Next, to control for other variables associated with T. gondii sero-
positivity in our previous work using the same population and the
50 IU/ml cutoff (Suvisaari et al., 2017), we included gender, age, ed-
ucation, region of residence, CRP, and cat ownership as covariates
besides T. gondii.
Analyses were repeated excluding those with a psychosis diagnosis
to investigate the association between psychotic-like symptoms and T.
gondii at the subclinical level.
Finally, the same regression analyses were conducted using
serointensity as a continuous variable, after logarithmic transformation
for normalization of the serointensity variable.
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3.1. Psychotic-like symptoms
5906 participants with toxoplasma infection data and CIDI interview
data were included (Table 2). Of these participants, 11.6% said that they
had experienced some of the presented psychotic-like symptoms. 6.7%
reported one symptom, 2.6% two symptoms, and 2.4% three or more
symptoms. The endorsement proportions for the individual 22 symp-
toms, ranging from 0.1 to 6.5%, are presented in Table 1. There was no
gender difference for the total number of symptoms or delusional
symptoms but women reported more hallucinatory symptoms than
men (p=0.018). Younger age was associated with havingmore symp-
toms (p b 0.001), specifically delusional symptoms (p b 0.001).
1.8% of the participants had talked about the symptoms with a doc-
tor or another mental health professional and 0.8% reported that the
symptom had interfered with normal life. Altogether, symptoms were
clinically relevant in 4.0% of the cases, with no significant gender differ-
ence. Younger age was associated with presence of clinically relevant
psychotic-like symptoms (p= 0.046).
3.2. Psychosis diagnoses
Any lifetime psychotic disorder was diagnosed in 2.6% and schizo-
phrenia in 0.7% of the participants, Table 2. Diagnoses were not related
to age or gender except for affective psychosis, which was diagnosed in
0.8% of men and 0.4% of women (p= 0.041).
3.3. Toxoplasma and psychotic-like symptoms
Seroprevalence of T. gondii in this sample was 19.4% (95% CI 18.1–
20.8). Clinically relevant psychotic-like symptoms were more common
among toxoplasma seropositive than among seronegative participants
(p= 0.001, Fig. 2). In a logistic regression model, toxoplasma seroposi-
tivity was significantly associated with clinically relevant psychotic-like
symptomswhen age, gender, education, region of residence, cat owner-
ship, and CRP were controlled for (Table 3).
Participants seropositive for T. gondii reported more psychotic-like
symptoms than the seronegative participants (p = 0.027, Fig. 3).
Predicting the number of reported psychotic-like symptoms in a nega-
tive binomial regression model, toxoplasma seropositivity was a signif-
icant predictor (Table 4).Table 2
Characteristics, psychotic-like symptoms and psychosis diagnoses of the participants, calculated
and sex.
Total, N= 5906a
Females (%) 51.9 [50.6, 53.2]
Age (years) 51.7 [51.3, 52.1]
Toxoplasma serointensity (IU/ml) 27.0 [25.9, 28.1]
Lifetime psychosis diagnoses (%)
Any psychotic disorder 2.6 [2.2, 3.1]
Functional psychosis 2.3 [1.9, 2.7]
Schizophrenia 0.7 [0.5, 0.9]
Other non-affective psychosis 0.9 [0.7, 1.2]
Affective psychosis 0.6 [0.4, 0.8]
Lifetime psychotic-like symptoms in CIDI-G
Clinically relevant psychotic-like symptoms (%) 4.0 [3.4, 4.5]
Number of all psychotic-like symptoms 0.23 [0.21, 0.26]
Number of hallucinatory symptoms 0.03 [0.03, 0.04]
Number of delusional symptoms 0.19 [0.17, 0.21]
CIDI-G, G section of the Composite International Diagnostic Interview, Munich version.
Statistically significant results shown in bold.
a In the total group, proportions (%) or means [95% confidence intervals]. Adjusted for samp
b In the subgroups, proportions (%) and means calculated as predictive margins [95% confidLooking at the number of hallucinatory symptoms separately,
toxoplasma seropositivity (incidence rate ratio (IRR) = 1.80, 95% CI
1.14–2.83, p=0.011)was a significant predictor (especially concerning
auditory hallucinations, see Supplementary Tables). The number of
delusional symptoms was also associated with toxoplasma (IRR =
1.48, 95% CI 1.13–1.93, p= 0.004).
The regression analyses were repeated after excluding those with a
lifetime DSM-IV psychotic disorder. Toxoplasma seropositivity predict-
ed both clinically relevant psychotic-like symptoms (OR 1.86, 95% CI
1.24–2.79, p = 0.003) and the number of psychotic-like symptoms
(IRR = 1.44, 95% CI 1.10–1.89, p = 0.008) in participants never diag-
nosed with psychotic disorder.3.4. Toxoplasma and psychosis diagnoses
Those with and without psychotic disorders assessed did not differ
in seroprevalence for toxoplasma (Table 2).
In logistic regression, any psychotic disorder was not predicted by
toxoplasma seroprevalence but there was a trend towards an associa-
tion (OR 1.45, 95% CI 0.99–2.14, p= 0.057).
In separate models, toxoplasma was neither significantly associated
with schizophrenia (OR 1.45, 95% CI 0.70–3.03, p=0.320) nor the other
psychosis diagnoses.3.5. Results using the serointensity
When antibodies to toxoplasma gondii were investigated as a contin-
uous variable instead of dichotomous seropositivity, the findings were
similar. In a logistic regression model of clinically relevant psychotic-like
symptoms, higher levels of antibodies against toxoplasma (OR 1.35, 95%
CI 1.15–1.59, p b 0.001) remained as the only significant predictor,
when age, gender, education, region of residence, cat ownership, and
CRP were controlled for. The number of reported psychotic-like symp-
toms was predicted by toxoplasma serointensity (IRR = 1.21, 95% CI
1.07–1.36,p=0.002). These resultswere repeatedwith the subset of par-
ticipants who had never been diagnosed with psychotic illness.
Psychoses were not associated with toxoplasma serointensity (OR
for any psychosis 1.18, 95% CI 0.98–1.43; OR for schizophrenia 1.12,
95% CI 0.79–1.59), when age, gender, education, region of residence,
cat ownership, and CRP where controlled for.by linear regression, negative binomial regression, or logistic regression adjusting for age
Seropositive, 19.4%b Seronegative, 80.6%b Group difference
59.8 [56.6, 63.0] 50.0 [48.6, 51.5] p b 0.001
54.9 [54.1, 55.7] 51.0 [50.5, 51.4] p b 0.001
78.2 [76.0, 80.4] 14.7 [14.4, 15.0] p b 0.001
3.4 [2.3, 4.4] 2.5 [2.0, 2.9] p= 0.069
2.7 [1.8, 3.7] 2.1 [1.7, 2.5] p= 0.167
0.9 [0.3, 1.4] 0.7 [0.4, 0.9] p= 0.459
1.2 [0.6, 1.8] 0.9 [0.6, 1.2] p= 0.388
0.7 [0.2, 1.2] 0.6 [0.4, 0.8] p= 0.648
5.9 [4.4, 7.3] 3.6 [3.0, 4.2] p= 0.001
0.29 [0.23, 0.35] 0.22 [0.19, 0.24] p= 0.027
0.05 [0.03, 0.06] 0.03 [0.02, 0.04] p= 0.052
0.23 [0.18, 0.28] 0.18 [0.16, 0.20] p= 0.052
ling design.
ence intervals]. Adjusted for sampling design, age, and sex.
Fig. 2. The proportion of participants with clinically relevant psychotic-like symptoms with 95% confidence intervals.
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4.1. The association between toxoplasma and the psychosis continuum
We used a large general population study sample to investigate
whether serological evidence of toxoplasma infection is associated
with the psychosis continuum.While the association between infection
and fully developed psychotic illnesses was not statistically significant,
the infection did increase the vulnerability for psychotic-like symptoms
in the study population representative of the whole adult population in
Finland.
T. gondii seropositivity and serointensity were associated with both
the number of psychotic-like symptoms and with clinically relevant
psychotic-like symptoms. Adjusting for CRP levels, indicating inflamma-
tion, did not change the effect.
To our knowledge, the association between T. gondii and the subclin-
ical positive dimension of psychosis in the general adult population has
not been studied previously. In an adolescent population sampleTable 3
Logistic regression model of clinically relevant psychotic-like symptoms; all variables
entered in the model simultaneously. Reference category in parentheses.
OR 95% CI for OR Sig.
Lower Upper
Gender (male)
Female 1.20 0.89 1.64 0.233
Age 0.99 0.98 1.00 0.166
Education (basic)
Secondary education 0.71 0.46 1.10 0.126
High education 0.92 0.60 1.41 0.703
Region of residence (Southern Finland)
Southwestern Finland 0.61 0.31 1.18 0.142
Western Finland 0.76 0.52 1.12 0.165
Eastern Finland 0.98 0.65 1.47 0.917
Northern Finland 1.02 0.64 1.63 0.946
C-reactive protein (CRP) 1.00 0.98 1.02 0.866
Cat ownership (never)
Previous 1.06 0.73 1.53 0.761
Current 0.92 0.55 1.55 0.757
Toxoplasma seroprevalence (negative)
Positive 1.77 1.26 2.48 0.001
OR, odds ratio.
CI, confidence interval.
Statistically significant results shown in bold.attenuated psychotic symptoms and toxoplasma were not correlated
(Wang et al., 2011). HoweverWang and colleaguesmeasured psychotic
symptoms with the mean score of positive items in the Community
Assessment of Psychic Experiences (CAPE), including also mild
psychotic-like experiences. Compared to CAPE, the items of CIDI-G are
tapping slightly more severe experiences.
Another previous study investigated antibodies against infectious
agents associating with positive symptoms in an ultra-high risk (UHR)
sample, suggesting that in some UHR individuals, onset of psychotic
symptoms may be associated with toxoplasma infection (Amminger
et al., 2007). Our positive finding of the association between positive
symptoms and toxoplasma is consistent with their results, although
the current sample was not selected for psychosis risk.
The most common experiences reported were referential thinking
and suspicion (items 2, 2B, and 6). Similarly to a cross-national WHO
surveys assessing 6 psychotic experiences with CIDI (McGrath et al.,
2015), symptoms were more common among women compared to
men. In the WHO study, the lifetime prevalence of psychotic experi-
ences was lower (5.8%), however (McGrath et al., 2015).
Some people reporting psychotic-like experiences in our study have
psychotic illnesses and for some, the symptoms express vulnerability
for psychotic disorders. However, the association between T. gondii se-
ropositivity and psychotic-like symptoms remained statistically signifi-
cant after people with a lifetime diagnosis of psychotic disorder were
excluded. According to previouswork, also subclinical symptoms are as-
sociated with heightened risk for psychosis (Bak et al., 2003). Although
they are mostly transitory, poorer outcome may emerge if additional
risk factors arise (van Os et al., 2009). Moreover, psychotic symptoms
are associated with worse health and functional capacity even when
the symptoms do not reach the clinical threshold for psychosis
(Nuevo et al., 2012). More longitudinal research is needed to address
the question of whether toxoplasma has a role in the development of
actual psychosis in those with attenuated psychotic symptoms.
It has been argued that elevated antibodies against toxoplasma
could also be a consequence of psychopathology. That is why studying
the antibodies before illness onset is beneficial. There are prospective
studies such as Pedersen et al. (2011) using a large cohort, where
individuals with high levels of IgG antibodies against toxoplasma had
an elevated risk of developing schizophrenia during follow-up up
to 16 years. The possible biological mechanisms between toxoplasma
infection and symptoms in the psychosis continuum include altered
dopamine transmission, neuro-inflammation, altered hormone
Fig. 3. Number of reported psychotic-like symptoms in the CIDI-G with 95% confidence intervals.
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al., 2016;Severance et al., 2016). There are also epidemiological similar-
ities between schizophrenia and toxoplasma (Yolken et al., 2009).
Only 5.9% of T. gondii seropositives had clinically relevant psychotic-
like symptoms in the current sample. Hence, most people with a history
of T. gondii infection do not develop psychotic-like symptoms. It may be
the timing of primary infection that matters in respect of the impact,
along with individual genetic factors, T. gondii strain (Xiao and Yolken,
2015), and type of initial infection.
In the current sample, the 1.45 OR for schizophrenia was similar to
the 1.53 OR found in the European region in the meta-analysis by
Sutterland et al. (2015). However, toxoplasma did not reach statistical
significance predictingmeeting criteria for DSM-IV psychotic disorders,
although there was a trend towards an association (p = 0.057). One
reason for this may be that psychotic diagnoses in the current studyTable 4
Negative binomial regression model of number of psychotic-like symptoms; all variables
entered in the model simultaneously. Reference category in parentheses.
IRR 95% CI for IRR Sig.
Lower Upper
Gender (male)
Female 1.18 0.95 1.46 0.136
Age 0.99 0.98 0.99 0.002
Education (basic)
Secondary education 0.69 0.53 0.91 0.008
High education 0.91 0.66 1.26 0.569
Region of residence (Southern Finland)
Southwestern Finland 0.56 0.39 0.82 0.003
Western Finland 0.56 0.39 0.81 0.002
Eastern Finland 0.99 0.73 1.35 0.947
Northern Finland 1.04 0.75 1.45 0.815
C-reactive protein (CRP) 1.00 0.98 1.02 0.865
Cat ownership (never)
Previous 0.97 0.73 1.30 0.840
Current 0.92 0.66 1.28 0.621
Toxoplasma seroprevalence (negative)
Positive 1.55 1.18 2.02 0.001
IRR, incidence rate ratio.
CI, confidence interval.
Statistically significant results shown in bold.were lifetime and many individuals with psychosis had been ill for a
long time. The sample size for diagnosed psychosis was also relatively
small. Psychotic disorders were more common in toxoplasma seroposi-
tive participants, although the difference was not statistically
significant.
4.2. Strengths and weaknesses
The strength of the current study is the large number of participants.
The whole Finnish population aged 30 and above was represented in
the Health 2000 study. However, Finland is a country with a relatively
low T. gondii seroprevalence (von Hertzen et al., 2006), and in the Euro-
pean region, the association of toxoplasma with schizophrenia is lower
than in many other regions of the world (Sutterland et al., 2015). The
studywas cross-sectional and timing of the infection could not be deter-
mined in the current study. IgM antibodies indicating acute infection
were not investigated. The study also lacked information on socioeco-
nomic background of the participants other than education.
Both psychotic illnesses and psychotic-like symptoms were investi-
gated in this study. While microbial agents have been investigated in
patients with established psychosis, not many studies have looked
into the possible association between subclinical positive symptoms
and infectious agents. However, the G section of the CIDI alone is not a
sensitive method for screening psychotic disorders (Perälä et al.,
2007;Kendler et al., 1996). Nevertheless, the number of psychotic-like
symptoms endorsed in the CIDI interview has been found to correlate
with a range of symptoms, including mood, sleep, energy, cognition,
and functioning (Nuevo et al., 2012), indicating clinical relevance.
4.3. Conclusions
We found that people with serological reactions to T. gondii had ele-
vated risk presenting with psychotic-like symptoms, pointing out need
for efficient prevention of T. gondii infections. Further studies are needed
to address the possible etiological effect of toxoplasma infection on the
risk of transition to psychosis. If toxoplasma infection continues to ap-
pear as a risk factor for psychotic-like symptoms and emerging psycho-
sis, this may affect the treatment of symptomatology across the
psychosis continuum.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2017.06.052.
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